Business

Crescita Announces Filing and Mailing of Special Meeting Materials and Receipt of Interim Order in respect of Arrangement with ClinActiv Holdings

Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“ Crescita ” or th...

articleCrescita Therapeutics, Inc.April 22, 20263/company/crescita-therapeutics-inc/news/crescita-announces-filing-and-mailing-of-special-meeting-materials-and-receipt-of-interim-order-in-respect-of-arrangement-with-clinactiv-holdings
Crescita Announces Filing and Mailing of Special Meeting Materials and Receipt of Interim Order in respect of Arrangement with ClinActiv Holdings

About this update from Crescita Therapeutics, Inc.

[{"type":"text","content":"Crescita Announces Filing and Mailing of Special Meeting Materials and Receipt of Interim Order in respect of Arrangement with ClinActiv Holdings\n\n\n .bwalignc { text-align: center; list-style-position: inside }\n \n\n\n\n Crescita Therapeutics Inc.\n \n (TSX: CTX and OTC US: CRRTF)\n \n (“\n \n Crescita\n \n ” or the “\n \n Company\n \n ”) announced today that it has filed and mailed the management information circular (the “\n \n Circular\n \n ”) and related materials in connection with the special meeting (the “\n \n Meeting\n \n ”) of its shareholders (the “\n \n Shareholders\n \n ”) to be held on May 14, 2026 in person at 2805 Place Louis-R-Renaud, Laval, Québec. The Meeting has been called for Shareholders to consider and, if deemed advisable, to pass a special resolution (the “\n \n Arrangement Resolution\n \n ”) approving the previously announced plan of arrangement (the “\n \n Arrangement\n \n ”) involving the Company, ClinActiv Holdings Inc. (“\n \n ClinActiv\n \n ”) and its wholly-owned subsidiary (the “\n \n Purchaser\n \n ”) pursuant to which the Purchaser will acquire all of the issued and outstanding common shares of the Company (the “\n \n Shares\n \n ”) in exchange for all-cash consideration, subject to the terms and conditions of the arrangement agreement dated March 14, 2026 (the “\n \n Arrangement Agreement\n \n ”). The target purchase price is $0.80 per Share, subject to upward or downward adjustment based on the Company’s net working capital balance at the closing of the Arrangement, subject to a minimum purchase price of $0.75 per Share.\n \n\n The board of directors of the Company (the “\n \n Board\n \n ”) (with Mr. Serge Verreault, the Company’s Chief Executive Officer, abstaining due to his interests in the Arrangement and related transactions) unanimously recommends that Shareholders vote FOR the Arrangement Resolution at the Meeting.\n \n\n\n Meeting and Circular\n \n\n\n The Meeting is scheduled to be held on May 14, 2026 at 9:00 a.m. (Toronto time) in person at 2805 Place Louis-R-Renaud, Laval, Québec. Shareholders of record as at the close of business on April 9, 2026 are entitled to receive notice of and vo...

More updates from Crescita Therapeutics, Inc.